Results 251 to 260 of about 499,108 (302)

Durable Response to Pazopanib (Tyrosine Kinase Inhibitor) in a Patient With EWSR1::CREM Gene Fusion Positive Intra-Abdominal Unclassified Epithelioid Sarcoma. [PDF]

Genes Chromosomes Cancer
Shafi S, Jones D, Pan X, Husain M, Rogers A, Oghumu S, Iwenofu OH.   +6 more
europepmc   +1 more source

Martinostat as a novel HDAC inhibitor to overcome tyrosine kinase inhibitor resistance in chronic myeloid leukemia. [PDF]

Clin Epigenetics
Yang H, Li V, Park SJ, Cheon SW, Lorant A, Mazumder A, Lee JY, Orlikova-Boyer B, Cerella C, Christov C, Kirsch G, Olberg DE, Bormans G, Kang HJ, Han BW, Schnekenburger M, Diederich M.   +16 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tyrosine Kinase Inhibitors

Current Cancer Drug Targets, 2010
Over the last ten years, several new and therapeutically relevant cancer drugs targeting tyrosine kinases signaling pathways have been developed. Tyrosine kinase inhibitors (TKIs) are a pharmaceutical class of small molecules, orally available, well-tolerated, worldwide approved drugs for the treatment of several neoplasms, including lung, breast ...
NATOLI, Clara, Perrucci Bruno, Perrotti Francesca, Falchi Lorenzo, IACOBELLI, Stefano, Consorzio Interuniversitario Nazionale per Bio Oncologia   +5 more
openaire   +4 more sources

Inhibitors of tyrosine kinase

Current Opinion in Oncology, 1997
This review covers the literature on significant studies of small molecule inhibitors of the epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), Flk-1, and src family tyrosine kinases from 1996 through mid-1997. During this period, there has been substantial progress in the
W D, Klohs, D W, Fry, A J, Kraker
openaire   +2 more sources

FLT3 Tyrosine Kinase Inhibitors

International Journal of Hematology, 2005
The receptor tyrosine kinase FLT3 is an important regulatory molecule in hematopoiesis and is expressed on the blasts in most cases of acute leukemia. Activating mutations of this receptor are present in roughly 30% of acute myeloid leukemia (AML) patients and are associated with a distinctly worse clinical outcome.
Mark, Levis, Donald, Small
openaire   +2 more sources

Tyrosine Kinase Inhibitors

2016
Breast cancer is the most common cancer in women worldwide. Although various subgroups are defined according to the expression of hormones and ErbB family receptors, it is well known that this disease is more heterogeneous than its classification system suggests.
Cakar B., Göker E.
openaire   +2 more sources

Tyrosine Kinase Inhibitors

Bulletin du cancer, 2012
Membrane receptors with tyrosine kinase activity and cytoplasmic tyrosine kinases have emerged as important potential targets in oncology. Starting from basic structures such as anilino-quinazoline, numerous compounds have been synthesised, with the help of tyrosine kinase crystallography, which has allowed to optimise protein-ligand interactions.
  +5 more sources

Tyrosine kinase inhibitor induced pancreatitis

Journal of Oncology Pharmacy Practice, 2012
Sorafenib and sunitinib are oral tyrosine kinase inhibitors, commonly used in the treatment of metastatic renal cell carcinoma. Known adverse events associated with tyrosine kinase inhibitors include hypertension and palmarplantar erythrodysesthesia. We report two cases of acute pancreatitis associated with tyrosine kinase inhibitors.
Adrienne, Sevin, Adrienne, Chen, Brad, Atkinson   +2 more
openaire   +2 more sources

HER-Targeted Tyrosine-Kinase Inhibitors

Oncology, 2002
Improved understanding of tumor biology has led to the identification of numerous growth factors that are involved in malignant transformation and tumor progression. Many of these factors induce cellular responses through receptors with intrinsic tyrosine kinase (TK) activity. Therefore, inhibiting receptor TK activity is a way to effectively block the
José, Baselga, Lisa A, Hammond
openaire   +2 more sources